What insurance policy changes affect code C32.0?

There are 5 tracked policy changes affecting code C32.0, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C32.0?

Payers that have issued tracked updates for code C32.0 include: Aetna.

How do I get notified when code C32.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C32.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C32.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

C32.0 Insurance Policy Changes

ICD-10 C32.0 is officially defined as "Malignant neoplasm of glottis." code C32.0 is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C32.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 1, 2026Medium impact
Voice Prosthesis for Voice Rehabilitation Following Total Laryngectomy (CPB 0560, reviewed 2026-08-26)
Aetna considers an indwelling tracheo-esophageal (TE) voice prosthesis medically necessary for voice rehabilitation after total laryngectomy when a laryngologist or speech-language pathologist recommends it and the selection criteria are met. Non-indwelling voice prostheses such as the Provox NiD are considered medically necessary under the same recommendation requirement, and hand-held artificial larynx devices are also considered medically necessary. Pneumatic bionic voice prostheses and the TE voice prosthesis insufflator are considered experimental, investigational, or unproven because their clinical value has not been established.
Aetna · Identified Aug 19, 2026Medium impact
Videostroboscopy (CPB 0305, reviewed 2026-04-17)
Aetna considers videostroboscopy medically necessary as a diagnostic procedure for detecting vocal cord pathology, such as polyps, invasive carcinoma, and vocal cord paresis or paralysis, in members who have received both a mirror-image and an endoscopic examination, where no abnormal function or clinical pathology was found with those tests despite persistent symptoms. Aetna considers videostroboscopy experimental, investigational, or unproven for all other indications because its effectiveness for those indications has not been established. Aetna also considers artificial intelligence-based assessment of videostroboscopy experimental, investigational, or unproven for the diagnosis of vocal fold sulcus (sulcus vocalis).
Aetna · Identified Aug 15, 2026Medium impact
Carbogen Inhalation Therapy (CPB 0428, reviewed 2026-07-09)
Carbogen inhalation therapy (5% carbon dioxide and 95% oxygen) is considered experimental, investigational, or unproven for bladder cancer, central retinal artery occlusion, cervical cancer, fracture healing, head and neck cancers, optic nerve damage or degeneration, prostate cancer, retinal artery occlusion, seizures, stroke, and sudden hearing loss. The policy lists no specific CPT or HCPCS code for carbogen inhalation therapy, and the ICD-10 diagnosis codes for these indications are listed as not covered for carbogen inhalation therapy. The policy was last reviewed 07/09/2026.
Aetna · Identified Aug 14, 2026Medium impact
Voice Prosthesis for Voice Rehabilitation Following Total Laryngectomy (CPB 0560, reviewed 2025-12-02)
Aetna considers hand-held artificial larynx devices medically necessary. Aetna considers indwelling tracheo-esophageal (TE) voice prostheses and non-indwelling voice prostheses, such as the Provox NiD, medically necessary when a laryngologist or speech-language pathologist recommends them for voice rehabilitation following total laryngectomy and the selection criteria are met. Indwelling TE voice prosthesis replacement every 3 to 6 months is considered medically necessary and is usually carried out as an outpatient procedure. Pneumatic bionic voice prostheses and the TE voice prosthesis insufflator are considered experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Durvalumab (Imfinzi) (CPB 0917, reviewed 2026-06-25)
Aetna considers durvalumab (Imfinzi) medically necessary for commercial medical plans when the criteria for a listed indication are met, and considers all other indications experimental, investigational, or unproven. Precertification is required of all Aetna participating providers and members in applicable plan designs, and Aetna considers members not eligible for Imfinzi when they have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy. Continuation of therapy is medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen, up to 12 months total for unresectable stage II or III NSCLC and up to 24 months total for limited stage SCLC.

Watch C32.0

Get one email when a payer policy names C32.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Voice Prosthesis for Voice Rehabilitation Following Total Laryngectomy (CPB 0560, reviewed 2026-08-26)

Videostroboscopy (CPB 0305, reviewed 2026-04-17)

Carbogen Inhalation Therapy (CPB 0428, reviewed 2026-07-09)

Voice Prosthesis for Voice Rehabilitation Following Total Laryngectomy (CPB 0560, reviewed 2025-12-02)

Durvalumab (Imfinzi) (CPB 0917, reviewed 2026-06-25)

What insurance policy changes affect code C32.0?

Which payers have updated policy for code C32.0?

How do I get notified when code C32.0 policy changes?

Why do payers change policies for code C32.0?